Tag: Biosimilars

Approximately 1.75 million Americans have age-related macular degeneration, and for many with the wet form, frequent injections of Eylea have been the standard. Now, several new options raise the key question: **What is the new alternative to Eylea?** These include longer-lasting treatments and biosimilars offering similar efficacy at potentially lower costs.

As of late 2025, there is no generic for Fasenra injection, because it is a biologic medication, not a traditional chemical drug. Instead of generics, complex biologics like Fasenra (benralizumab) may one day have "biosimilars," but these are not yet approved.

Despite the prevalence of generic medicines, the brand-name biologic Taltz (ixekizumab) currently has no generic version or biosimilar available. This is because Taltz is a complex biologic drug, not a simple chemical compound, which affects its generic and biosimilar development pathway.

Enbrel is a biologic drug, which means it does not have a traditional generic version, but instead has biosimilars. As of September 2025, no biosimilars for Enbrel are available on the market in the U.S. due to patent decisions, though some have received FDA approval. Patients asking "What is the generic version of Enbrel?" must understand this key distinction to navigate their treatment options and manage costs.

According to AbbVie's financial reports in late 2024, the interleukin-23 inhibitor Skyrizi officially surpassed the TNF-alpha inhibitor Humira in quarterly and annual sales, marking a major market shift. This directly answers the question, is Skyrizi overtaking Humira?, and signals a new era in the treatment of autoimmune conditions.

Tepezza (teprotumumab-trbw) was the first FDA-approved medication specifically for Thyroid Eye Disease in 2020. For many patients, the high cost of this brand-name treatment raises the question: is there a generic for Tepezza?

For years, the anti-inflammatory drug Humira (adalimumab) has been a dominant force in the pharmaceutical industry, recognized as the world's top-selling prescription medication. This widespread use has made it a historical contender for what is the most prescribed biologic, treating millions of people suffering from chronic inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. However, the landscape of the biologic market is shifting dramatically with the introduction of numerous biosimilars and other innovative therapies.

VPRIV (velaglucerase alfa) was approved by the U.S. Food and Drug Administration (FDA) in 2010 for long-term treatment of Type 1 Gaucher disease. For those asking what is the generic for VPRIV, it is important to understand that this medication, as a biologic, does not have a generic version in the traditional sense.

The global biologics market was valued at over $461 billion in 2022 and is projected to surpass $1 trillion by 2030 [1.10.1]. This guide answers the key question: **What class of medications are biologics?** and explores why they are a revolutionary force in modern medicine.

First approved by the FDA in 1997, rituximab has since revolutionized the treatment of several B-cell cancers and autoimmune diseases. The journey to market involved multiple companies, and today, an expanding list of manufacturers produce this essential medicine. So, which company makes rituximab, and what do you need to know about the different versions?